I

Iovance Biotherapeutics
D

IOVA

1.74500
USD
-0.01
(-0.29%)
Market Closed
Volume
144,152
EPS
-1
Div Yield
-
P/E
-1
Market Cap
582,715,505
Related Instruments
B
BEAM
0.060
(0.30%)
19.950 USD
BMY
BMY
-0.525
(-1.10%)
47.080 USD
C
CRSP
0.455
(0.88%)
52.120 USD
E
EDIT
0.02000
(0.78%)
2.57000 USD
GILD
GILD
-0.760
(-0.68%)
110.760 USD
JNJ
JNJ
0.570
(0.37%)
156.110 USD
MRNA
MRNA
0.195
(0.64%)
30.480 USD
N
NTLA
-0.020
(-0.19%)
10.710 USD
PFE
PFE
0.110
(0.43%)
25.440 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
More
News

Title: Iovance Biotherapeutics

Sector: Healthcare
Industry: Biotechnology
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.